We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
-1.67%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$954M
AUM Growth
-$71.4M
Cap. Flow
-$2.48M
Cap. Flow %
-0.26%
Top 10 Hldgs %
46.58%
Holding
81
New
11
Increased
16
Reduced
19
Closed
9

Top Buys

1
AMPH icon
Amphastar Pharmaceuticals
AMPH
+$20.6M
2
THOR
THORATEC CORPORATION
THOR
+$14.2M
3
VOLC
VOLCANO CORPORATION COM STK
VOLC
+$13.8M
4
PGNX
Progenics Pharmaceuticals Inc
PGNX
+$11.5M
5
KND
Kindred Healthcare
KND
+$10.8M

Top Sells

1
BDSI
BioDelivery Sciences International, Inc.
BDSI
+$19.4M
2
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$15.5M
3
NVDQ
Novadaq Technologies Inc.
NVDQ
+$14.7M
4
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$13.5M
5
AMAG
AMAG Pharmaceuticals
AMAG
+$9.6M

Sector Composition

1 Healthcare 78.52%
2 Consumer Discretionary 0.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CPRX icon
51
Catalyst Pharmaceutical
CPRX
$4.65M 0.49%
1,400,000
-1,000,000
-42% -$2.61M
FLXN
52
DELISTED
Flexion Therapeutics, Inc.
FLXN
$3.89M 0.41%
213,204
-50,000
-19% -$724K
TRVN
53
DELISTED
Trevena, Inc.
TRVN
$3.85M 0.4%
960
– –
CASM
54
DELISTED
CAS Medical Systems, Inc.
CASM
$3.72M 0.39%
1,918,296
+493,500
+35% +$851K
ARAY icon
55
Accuray
ARAY
$30.8M
$3.63M 0.38%
+500,000
New +$4.06M
LBMH
56
DELISTED
LIBERATOR MED HLDGS INC (NY)
LBMH
$3.6M 0.38%
1,150,837
-1,907,807
-62% -$6.03M
CCXI
57
DELISTED
ChemoCentryx, Inc.
CCXI
$3.6M 0.38%
800,000
-250,000
-24% -$1.32M
SCTL
58
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$3.47M 0.36%
1,306,997
+557,500
+74% +$2.71M
RDHL
59
Redhill Biopharma
RDHL
$4.29M
$3.47M 0.36%
263
– –
NGNE icon
60
Neurogene
NGNE
$744M
$3.4M 0.36%
25,525
– –
MRTX
61
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$3.23M 0.34%
184,756
– –
IRMD icon
62
iRadimed
IRMD
$1.24B
$2.88M 0.3%
+410,884
New +$3.72M
CASC
63
DELISTED
Cascadian Therapeutics, Inc.
CASC
$2.88M 0.3%
+250,000
New +$3.82M
AKTX
64
Akari Therapeutics
AKTX
$19.3M
$2.87M 0.3%
59
– –
ANTH
65
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$2.5M 0.26%
162,703
+66,912
+70% +$1.41M
NVDQ
66
DELISTED
Novadaq Technologies Inc.
NVDQ
$2.48M 0.26%
195,017
-1,006,600
-84% -$14.7M
PHIO icon
67
Phio Pharmaceuticals
PHIO
$12M
$2.25M 0.24%
2
– –
ALBO
68
DELISTED
Albireo Pharma Inc
ALBO
$2.22M 0.23%
44,334
– –
TNXP icon
69
Tonix Pharmaceuticals
TNXP
$198M
– –
0
– –
STRR
70
DELISTED
Star Equity Holdings
STRR
$1.31M 0.14%
6,650
– –
INFI
71
CALL
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$495K 0.05%
1,500
– –
HZNP
72
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$450K 0.05%
+2,000
New +$23.2K
AGEN
73
Agenus
AGEN
$209M
– –
-60,172
Closed -$3.8M
HAE icon
74
Haemonetics
HAE
$3.54B
– –
-3,600
Closed -$127K
LPCN icon
75
Lipocine
LPCN
$18.4M
– –
-15,561
Closed -$1.61M
1 2
3
4

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q3 2014 Portfolio in Review

As of Q3 2014, Broadfin Capital held 81 positions worth $954M, down 7% from $1.03B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Broadfin Capital's Q3 2014 filing shows 11 new, 16 increased, 19 reduced and 9 closed positions. Its largest new stake was Amphastar Pharmaceuticals: 1,977,854 shares worth $23M. The largest sale was BioDelivery Sciences International, Inc., an estimated $19.4M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 80% a quarter earlier, followed by Consumer Discretionary.

  • Broadfin Capital's largest Q3 2014 buy was Amphastar Pharmaceuticals: 1,977,854 shares worth $23M.
  • Broadfin Capital added most to Progenics Pharmaceuticals Inc in Q3 2014, an estimated $11.5M increase.
  • Broadfin Capital's biggest Q3 2014 reduction was BioDelivery Sciences International, Inc., cutting an estimated $19.4M.
  • Broadfin Capital fully exited Option Care Health in Q3 2014, selling an estimated $9.58M.
  • Broadfin Capital's ten largest holdings make up 47% of its $954M portfolio in Q3 2014.
  • Broadfin Capital opened 11 new positions and closed 9 in Q3 2014.
  • Broadfin Capital's portfolio value fell 7% quarter-over-quarter to $954M.

Based on Broadfin Capital's 13F filing for Q3 2014, filed 14 Nov 2014.